Exciting Developments for Molecular Partners at EANM 2024
Molecular Partners AG is poised to showcase groundbreaking advancements in oncology with their upcoming presentations at the European Association of Nuclear Medicine (EANM) Congress. This event is significant for the clinical-stage biotech as they unveil their leading candidate, MP0712, a ²¹²Pb-labeled Radio-DARPin therapeutic specifically designed to target DLL3 in small cell lung cancer (SCLC).
The Role of MP0712 in Cancer Treatment
In preclinical models, MP0712 has demonstrated remarkable efficacy, characterized by low kidney accumulation and impressive tumor uptake. The treatment not only leads to significant tumor growth inhibition but also maintains a strong safety profile in vivo. This highlights the potential of MP0712 as a promising therapeutic option for patients struggling with SCLC.
Details of the Upcoming Presentation
The presentation will take place on October 22, 2024, within the M2M Track of the EANM congress. The focus will be on the preclinical assessment of MP0712, emphasizing data that supports its application in treating SCLC. The presentation will feature insights into the biodistribution profile, antitumor activity, and safety considerations of this innovative therapeutic approach.
Presentation Overview
The specifics of the session include:
- Title: Preclinical Assessment of Lead-212 (²¹²Pb) Radio-DARPin Therapeutic (RDT) Targeting Delta-like Ligand 3 (DLL3) in Small Cell Lung Cancer (SCLC)
- Presentation Number: OP-535
- Session Timing: October 22, 2024, from 8:00 to 9:30 a.m. CET
- Presentation Time: 9:20 to 9:30 a.m. CET
Understanding DARPin Therapeutics
DARPin therapeutics bring a revolutionary shift in how targeted treatments are designed. Based on naturally occurring binding proteins, they offer unparalleled multi-functionality and specificity in targeting multiple receptors. Their small size benefits targeted therapy delivery, enhancing the efficacy of treatment. As Molecular Partners continues to refine its DARPin platform, they aim to promote rapid and cost-effective drug development.
About Molecular Partners AG
Molecular Partners AG, a front-runner in clinical-stage biotech, focuses on pioneering DARPin therapeutics to address medical challenges that existing drugs do not adequately manage. The company is heavily invested in oncology, working to create unique treatment solutions through proprietary programs and strategic partnerships.
About Orano Med SAS
Orano Med specializes in advancing targeted therapies against cancer through its innovative work with lead-212 (²¹²Pb). Known for its potential as a powerful therapeutic agent, ²¹²Pb is leveraged in various treatment modalities, making it a critical component of modern cancer therapies.
Contact Information
For inquiries regarding this presentation or the company's developments:
Seth Lewis, SVP Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35
Frequently Asked Questions
What is MP0712?
MP0712 is a ²¹²Pb-labeled Radio-DARPin therapeutic targeting DLL3 for treating small cell lung cancer.
When will Molecular Partners present at EANM 2024?
The presentation is scheduled for October 22, 2024.
What are the benefits of DARPin therapeutics?
DARPins offer high specificity and multi-target functionality, enhancing drug efficacy and safety profiles.
Who is co-developing MP0712?
MP0712 is co-developed by Molecular Partners and Orano Med.
What is the focus of the presentation at EANM?
The presentation will focus on the preclinical assessment and promising results of MP0712 in targeting SCLC.
